Rewalk Robotics Ltd
NASDAQ:RWLK
Earnings Call Analysis
Summary
Q3-2023
ReWalk Robotics achieved a near 400% increase in Q3 sales, reaching $4.4 million. This surge was driven by a 65% rise in legacy ReWalk revenue, notably in the U.S. and Germany, with the balance from the AlterG acquisition. The company also reported significant investments to support policy changes with CMS and the VA. Expecting payments from Medicare to start in January 2024, ReWalk anticipates finalized market pricing by Q2 2024. They are actively enrolling Medicare patients for their exoskeletons. Two new products will launch in 2024: a new ReWalk design and an Ultra G model aimed at the independent clinic market. Their strategic growth resulted in 70% more exoskeleton revenue and a 50% increase in MyoCycle FES cycle sales. The U.S. field team is set to become the largest in the industry, totalling approximately 50 individuals.
You don't have any saved screeners yet
Hello, and welcome to the Q3 2023 ReWalk Robotics Limited Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded. I'd now like to turn the conference over to Michael Lawless. Please go ahead, sir.
Thank you, Keith. Good morning, and welcome to ReWalk Robotics' Third Quarter 2023 Earnings Call. I'm Mike Lawless, ReWalk Robotics' Chief Financial Officer. And with me on today's call is Larry Jasinski, our Chief Executive Officer. Earlier this morning, ReWalk issued a press release detailing financial results for the 3 and 9 months ended September 30, 2023. The press release and a webcast of this call can be accessed through the Investor Relations section of the ReWalk website at rewalk.com. Before we get started, I'd like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act.
These forward-looking statements are based on information available to ReWalk management as of today and involve risks and uncertainties, including those noted in our press release and ReWalk's filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements.
ReWalk specifically disclaims any intent or obligation to update these forward-looking statements, whether as a result of new information, future developments or otherwise except as required by law. A replay will be available shortly after the completion of the call accessible from the dial-in information in today's press release. The archived webcast will be available in the Investor Relations section of the company's website.
For the benefit of those who may be listening to the replay or the archived webcast, this call was held and recorded on November 14, 2023. Since that date, may have made subsequent announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings for the most update information. And with that, I'll turn the call over to ReWalk's CEO, Larry Jasinski.
Thank you, Mike. Good day to all. Since our last financial call, a number of very important events have occurred that we believe have the potential to dramatically change our revenue trajectory and will put ReWalk on a path to profitability. These amounts are the strategic acquisition of a growing profitable entity, material decisions by the Center for Medicare and Medicaid Services, CMS, on our path to ensure Medicare beneficiaries have access to our life-changing products, progress with the Veterans Administration to make our system animal and FDA clearance introduction of truly breakthrough technology advancements to our system. Let me talk through each of these in order. Together, these represent a watershed moment for the company. Equally important, we will be better positioned to fulfill the mission of our founder, which was to empower a large segment of the spinal carting community with the ability to stand eye to eye and walk down the street with all of us. The importance of our successful integration of AlterG is significant in having both the financial size and infrastructure to succeed by building on the government policy decisions. From a financial perspective, from August 11 through the end of Q3, AlterG was profitable, and we anticipate it will continue its profitability in Q4. As we combine the ReWalk and Ultra G sales organizations on January 1, 2024, we will have the largest U.S. field organization in the exoskeleton industry. This expanded team provides us with the infrastructure for the furthest reach and highest quality of support for the industry. For reimbursement, working closely with multiple systems at the center for Medicare and Medicaid Services and CMS, we received a health care common procedure coding system, Hectic code in 2020. Then on November 2, 2023, we achieved an assignment to a benefit category for lump sum payments to begin in January 2024. On November 6, a preliminary pricing proposal was published with a request to provide more data as a basis to finalize current market pricing by the start of Q2 2024. During this process, we continue to aggressively enroll Medicare patients submitting about 20 cases in 2023 and a similar number being submitted in Q1 2024. With the Veterans Administration, we focused in 2023 on reestablishing strong supply pathways post COVID with the core spinal cord injury centers as we progress from 3 fully active centers to 9. Some VA centers are conducting direct patient selection of control, but then allowing contracted local training in institutions or clinics close to home of the veteran. This is through the choice program, which allows funding for localized training. On Veterans Day weekend, CBS interviewed Brittany Elliot, a marine who participated in the VA's randomized trial with the ReWalk exoskeleton. She spoke about how the ReWalk changed their life and how she lost 4 years of walking while waiting for a personal system after the VA's clinical trial. She was in Washington, advocating on behalf of the STAM Act as the spinal trauma access to new Devices Act. This important bill has by part of the support and was led by representatives Burden, Dingle, Boast and Brownly in the U.S. House of Representatives. It was also endorsed by the Paralyzed Veterans of America, PVA and by disabled American veterans. This proposed legislation requires that each spinal cord injury veteran be offered the potential supply of an exoskeleton if they are medically qualified as determined during their annual example. It also adds reporting metrics for SCI centers to document their process in evaluating the disabled veterans that use their service.
From a technical perspective, our breakthrough designated FDA clearance allows us to supply Medicare beneficiaries and injured veterans with a product that allows the greatest utilization in daily life as they can now navigate stairs and curves when they're out walking. In parallel, we have 2 new products planned for launch in 2024. The first is a new ReWalk exoskeleton design that has many improved features and adds cloud connectivity, all of which will aid utilization and make the system easier to use. The other is a new Ultra G model that will offer a model for greater penetration into an untapped segment of the independent clinic market. Before we move to the financial metrics for Q3, I want to give a few business measurements that we will discuss in both the financial and operating detail discussions for the quarter and period ahead.
Q3 sales of $4.4 million represents a nearly 400% increase over Q3 2022 that is comprised of a 65% increase in ReWalk revenue and the balance is the addition of AlterG for the last 6-plus weeks of the quarter. Q3 and Q4 expenses include meaningful investment in CMS and VA policy support, along with the integration expense, which are all expected to substantially decrease in 2024 and but are essential now to set the stage for future patient access and for ReWalk success. The combined U.S. field team will be approximately 50 individuals, including a clinical evaluation group, a sales team covering the entire country, a clinical training team, a reimbursement team and a field service team. And as per our strategic direction, meaningful growth is now occurring in both the ReWalk and Alder product lines. I'd now like to turn the call back over to Mike for more financial detail. Mike?
Thanks, Larry. Before I review the results of the quarter, I want to first comment that our Q3 '23 GAAP results reflect purchase accounting adjustments, transaction expenses in integration costs from the acquisition of AlterG, which can obscure investors' visibility to the underlying operational performance of ReWalk. In order to facilitate understanding of both the GAAP and the operational results of ReWalk, I'm going to discuss Q3 on both the GAAP and also on a non-GAAP basis, which excludes the purchase accounting adjustments, transaction expenses, integration costs and stock compensation expense. The reconciliation of the non-GAAP to GAAP results is provided in today's earnings release. Okay. First, the revenue. ReWalk Robotics reported revenue of $4.4 million in the third quarter of 2023 compared to $0.9 million in the third quarter of 2022, up $3.5 million. The biggest factor in our growth in the third quarter was the acquisition of AlterG, which contributed revenue of $2.9 million, which was the revenue generated from the date of the acquisition on August 11 through the end of the quarter. AlterG's revenue performance was in line with our internal expectations. For the legacy ReWalk product lines, Q3 '23 revenue was $1.5 million compared to $0.9 million for Q3 '22, up 6 -- $0.6 million or 65%. The increase in legacy ReWalk revenue was a result of continuing sales momentum in the U.S. states and sequential improvement in Germany. In total, exoskeleton revenue was up 70% in Q3 '23 versus Q3 '22, while our distributed product line, the MyoCycle FES trading cycles had another strong quarter with revenue up over 50% from Q3 '22. Turning to our pipeline metrics within the current markets for the ReWalk product line, which includes individuals covered by the Veterans Administration and workers' compensation insurance in the U.S. and by private insurance in Germany. The current pipeline of active rentals consists of 26 cases, up 4 from last quarter, which is broken down with 21 in Germany and 5 VA rentals. As of September 30, our overall number of ReWalk cases in process is 68 with 58 in Germany and 10 in the U.S. The AlterG business ended the quarter with orders for 83 systems in backlog, which represents a healthy start to Q4 '23. The AlterG business typically carries a backlog, which represents a portion of the units that are sold in the upcoming quarters with the balance of the revenue generated through subsequent orders that ship within the quarter. As a reminder, the pipeline figures for ReWalk systems I described do not include cases that would be eligible for Medicare reimbursement. Once Medicare claims that we have already submitted as well as new ones, which we will continue to submit begin to be processed and paid by the Medicare contractors, they will convert to revenue that is additive to the revenue from our traditional pipeline of VA and workers' comp cases. Moving to gross profit. In Q3 '23, our GAAP gross profit was $0.9 million or 19.6% of revenue compared to $0.2 million or 24.9% of revenue in Q3 '22. This decrease of 5.3 percentage points in gross margin was a result of purchase accounting adjustments from the AlterG transaction. In Q3 '23, we recognized additional cost of sales of $0.6 million for the step-up of the value of existing inventory of AlterG at the closing of the acquisition that was later sold during Q3 '23. In addition, we incurred $0.5 million from the amortization of intangible assets that were created when the purchase price for AlterG was allocated across AlterG's balance sheet. Excluding the impact of these 2 purchase accounting adjustments and stock comp expense, non-GAAP gross profit was $2.0 million or 45.1% of revenue for Q3 '23, up 19.7 percentage points from Q3 '22.
This increase in gross margin on a non-GAAP basis was primarily a result of higher volumes of ReWalk and MyoCycle units sold, leveraging our fixed production costs and an increase in our average selling price due to a change in sales mix. AlterG also provided a slight benefit to the consolidated gross margins for the portion of the quarter that we owned it.
GAAP operating expenses were $8.8 million in Q3 '23, up $3.1 million or 56% compared to $5.7 million in Q3 '22. Within the functions, GAAP R&D expense was $1.3 million in Q3 '23 as compared to $1.1 million in Q3 '22, an increase of $0.2 million or 18% due to the acquisition of AlterG which contributed $0.3 million to the increase. For the legacy ReWalk business, which excludes the contribution of AlterG, R&D was $0.9 million, a decline of $0.1 million or 14% primarily due to lower spending on subcontractors and consultants on the ReWalk 7 projects since we are in the final stages towards FDA submission. GAAP selling and marketing expense was $4.1 million in Q3 '23 as compared to $2.6 million in the prior quarter, up $1.5 million or 58%.
GAAP selling and marketing expense in Q3 '23 included $0.2 million of amortization of intangibles from the acquisition of AlterG. On a non-GAAP basis, selling and marketing expense was $3.8 million, up $1.2 million or 50%. The largest single factor in the increase was the contribution of Ultra G, which added $0.7 million expense to the quarter. For the legacy ReWalk business, which excludes the contribution of AlterG, non-GAAP selling and marketing expense was $3.1 million in Q3 '23, an increase of $0.6 million or 23%. The increase in legacy ReWalk selling and marketing expense was primarily due to higher consulting fees associated with CMS reimbursement related activity as we had heightened efforts in this area during Q3 as well as higher trade show expenses. GAAP, general and administrative expense was $3.5 million in Q3 '23 as compared $2 million in Q3 '22, up $1.5 million or 73%. GAAP G&A expense included $37,000 of amortization of intangible assets from the acquisition of AlterG and $1.3 million of M&A-related transaction costs. On a non-GAAP basis, G&A expense was $1.9 million, up $0.1 million or 8%. AlterG contributed $0.2 million to this increase. Legacy ReWalk, non-GAAP G&A in Q3 '23 was down slightly versus the spending level in Q3 '22 or about 2%. Our GAAP operating loss for the third quarter was $7.9 million compared to an operating loss of $5.4 million in the third quarter of 2022. The non-GAAP operating loss, which excludes the items I've discussed previously, was $4.9 million in Q3 '23 as compared to $5.1 million in Q3 '22. AlterG was profitable in the quarter and contributed to the improvement in the non-GAAP operating loss performance. We ended the quarter with $3.2 million in cash and cash equivalents and no debt. Our operating cash usage in Q3 was $7.4 million which is higher than the recent quarters due to approximately $2 million in cash paid for the onetime M&A-related expenses and meaningful investment in CMS and VA policy support. We expect the incremental M&A-related expenses expenditures to be significantly lower in Q4 '23 than the prior quarter and for our revenue to be higher in relation to our cost structure. So the cash burn rate in Q4 should improve considerably from Q3 '23 levels. For Q4 '24, we expect a sequential increase in legacy ReWalk revenue and a full quarter's contribution of revenue from AlterG. On a going forward basis, our top financial priority will be to reduce significantly and eventually eliminate our cash burn rate. With the Ultra G acquisition completed and the integration underway, our goal is to grow our top line in a capital-efficient way to minimize investment in additional resources and to prioritize our spending to only support our core objectives. Lastly, I want to provide an update on the status of our listing requirements for NASDAQ. As you may know, back in October, we were notified by NASDAQ that our second 180-day compliance period had expired and that we were still in noncompliance with NASDAQ Listing Rule 5550A to maintain a minimum bid price of $1 per share. We responded to this notification with a request for a hearing before the NASDAQ Hearings Panel and also subsequently requested an expedited review since we qualified for this. We received back a response that the expedited review resulted in us being granted an extension until January 31, 2024, to regain compliance with Rule 5550A. We continue to be committed to driving improved fundamentals and financial performance of ReWalk to regain compliance with this role. With that, I'd like to turn the call back to Larry for further remarks.
Thank you, Mike. I'd now like to provide a little more detail on our CMS activities, VA implementation efforts and our financial operating direction. In 2023, with CMS Medicare, we have submitted about 20 [indiscernible] claims and paused new submissions momentarily to implement claims using the newly assigned benefit category with lump sum payment beginning January 2024. We are not yet including these deliveries in our revenue forecast until the timing and payments are established. Our immediate focus is participate in the upcoming HCPC November 29 meeting and providing the requested data, which reflects our current 2023 commercial updated technology. CMS published the preliminary price based on a 2020 claim and they noted they welcome data on current pricing and product models. The data we will present at this meeting on the 29th is based on the submitted claims to Medicare since April 2023. These claims reflect the accurate list price of the device to be taken in consideration by CMS in their pricing formula. Historically, once this review houses is complete, a final price will be published in late January or early February with an effective date of April 1, 2024. In parallel, we will begin to educate physicians on the specific inclusion and exclusion criteria so they can determine which of their patients may potentially benefit with this technology. We have aggressive plans to collaborate with commercial payers and the spinal cord community to increase awareness of these achievements and access to the technology. We will also work with the spinal core community directly to ensure they understand that access has become a reality after all the years with no available pathway. We will utilize the mix of online effort, media publicity and telephonic or Zoom support, provide information to community as well as planned, targeted approaches with engaged payers. Our large sales presence will be also a key part of our educational efforts in the market. We're also excited about the support we are seeing with our new VA centers and the initiatives by Congress and the Senate to broaden awareness and consideration of walking once again. The support in parallel for the Stand Act by the Paralyzed Veterans of America, and the disabled veterans community is fantastic advocacy for this community. VA remains the leader in research on spinal cord injuries, and although it has taken some time, with the individual spinal cord injury centers to provide products, they are leading the way in enabling walking in everyday life. The stand-back that is moving through Congress has 4 key elements: one, annual exoskeleton evaluations are codified in law for those veterans who seek their care through the VA. Two, the VA provides Congress updates on progress in terms of numbers of evaluations, training and device approvals. And three, it includes exoskeleton manufacturers and other external stakeholders when considering changes to the clinical practice guidelines published at the evaluation, training and procurement of exoskeleton devices. And finally, four, appropriate usage of exoskeleton devices has become a measurable element of the overall performance metrics for leadership within existing veterans integrated service networks, or VA regions. Our role is to use our enlarged field organization to provide the training and support needed to assist these VAs as needed with our innovative technology. I would now like to address our operational direction for the rest of 2023 and as we look into 2024. 2022 and 2023 were investment years to advance government policy, to build our infrastructure organically and with an acquisition to advance our technology. As we close 2023, we are changing to a new operating phase that is based on execution and building on the tremendous successes of 2022 and 2023. For 2024, revenue must grow, investment must decrease, and operating efficiency becomes a paramount measurement. We will hold off on providing 2024 specific growth expectations until we gain more detail on the CMS final payment level and on the timing of the first 20 to 40 cases for payment. Then we will have information and experience to provide more detail. As 2024 is a financial execution year, our burn rate must decrease substantially. Combined with our revenue growth, we see decreases in certain investment areas as key priorities change. We see decreases in investment and government policy, and we begin to see synergy in the operations of the combined entity. I look forward to defining these further in our Q4 earnings call. We simply had a fantastic Q3 and early Q4 after years of building investment. We are optimistic about the future and the knowledge that realliance will endure for those who need them based on the foresight and poly [Audio Gap] of CMS and the VA. We now have all the needed elements for growth and execution. It's up to us to be financially prudent and to work just as hard in this new phase as we have during these years of development. Thank you, everyone, for your time today, and we'd like to open up the forum to questions. Please.
[Operator Instructions] And the first question comes from Banca Math from H.C. Wainright.
Let's start up with -- so in terms of that the new business, as you said the first quarter that you have on your belt, it has been profitable, which is good news. Can you comment a little bit about -- but how AlterG's progressing in your hands? And also, how do you see cross-selling from AlterG to ReWalk because Reebok is also entering and the execution phase as you call it.
Again, I think there's parts of that for me and for Mike. First, we are really thrilled with how this is progressing and how it's come together. And our favorite measurement of this is how well we hit the ground running in terms of the acquisition for revenue results and for beginning to integrate. We have taken this period to focus on hitting the numbers for Q3 and Q4. And in parallel to do a lot of work on the proper structural setup for this combined organization that will go into place on January 1. And we've outlined a very extensive program to have everybody trained, but what we're going to wind up having is a sales organization whose reach is just dramatically broader than it was as 2 stand-alone entities. And the synergistic component of this is all of the 600 exoskeleton injury centers in the United States it's have ultras in them. So they are very good connection action points. And the larger organization for AlterG's benefit as they will now have more territories in the -- as they launch a new product in 2024, they can get to the smaller clinics on a better geographic basis. So the operating structure that is taking effect as of the first of January, is what we believe is the right structure to benefit both companies, us to work on CMS and VA from the ReWalk end and us, the other part of us to be able to get to these clinics with the new product and broader reach on AlterG's line. Did you want anything further on the financial side of this? Or does that answer your question, RK?
This is good. I'll come to the finance in a minute. But before we get there, in your prepared remarks, you also made comments on a new AlterG model as well as a new ReWalk model. Can you give some highlights about what is new in these stores models that you are planning to planning to start commercialize?
Yes, we haven't completely advertising as to what we're bringing to the market in a big sense. But internally, there's slightly different goals in both. For AlterG, we have a model that will play to a broader and newer audience. It's a device that is designed really specifically to make the needs of smaller private clinics. And now with a larger team that we can call on those clinics, that's why we believe this fits well. So it's an additional product line and they're offering for a segment that they really haven't pursued at a high level. And it is a very economic and very good operational system for the small private clinic. So that's the AlterG model, and we'll begin that launch in the first -- late first half of the year is our intention. On the ReWalk side, we have a product with a number of improvements that we're focusing on making them easier to use. So it's not a radically different product but is a product that is powered differently in terms of battery structure and life. It can offer multiple speeds, which makes it easier to use in the community. And we've improved the cloud connectivity, which, frankly, we want to use to help drive utilization because data will be available, and we can help users understand use, and we can encourage them to use it even more with these metrics. So products are a little bit different. One driven at utilization, the other one is a new market segment.
So one more question for you operational side. So as we enter into potentially good growth in the U.S., do you think Europe will also contribute to that growth in '24?
Yes. We do expect growth in Europe. I think the rate of growth in the United States because of the CMS size of the segment and the VA is going to be the majority of our growth. I think growth in Europe will be driven a little bit by them just reopening it a little more. They've been slow to get their clinics going at the highest levels from a personnel point of view over the course of the year, personnel shortages and things of that type. But we do see expansion in Europe, specifically within the ReWalk side. And on the AltraG side, they have a very good distribution network that we believe we'll be able to build on as well.
A couple of quick questions on the financial side. So Reebok sales came in at $1.5 million for the quarter. What drove that growth in the real business and also for AlterG sales? You stated $2.9 million this quarter so what are we comparing that against to say sequentially, how much has it grown? And I'll stop right there.
Sure. Good questions. First, I want to clarify, I think I misspoke on the call about the cash balance. The correct cash balance is $32.6 million in case I misread that as I was describing the cash balance. So in terms of the growth on the ReWalk side, it was really across the board in terms of -- there was, like I said, sequential improvement in Germany and Europe. I would -- but I would say that the majority of the growth was really driven by the U.S and VA -- sales to the VA for the exoskeletons as well as continued strong performance by the MyoCycle product line.
And then on the AlterG sales?
Yes. So the AlterG sales, I would say, they don't necessarily, it's not a levelized level of sales through the quarter. It is -- it tends to be with a lot of capital equipment products tends -- or a lot of business in general tends to be towards the second half, more towards the second half of the year. So you can't sort of just take that -- the $2.9 million and just assume that was leveled throughout the quarter. So we've described in the past, the business as being about a $20 million business. So you can sort of like -- we're focused by giving a guidance at this stage, so I'm being a little bit coy, but you can make a determination of what you think the business would do based on the how we've described it on an annualized basis. I think we'd like to own it for one more quarter and kind of go through the full quarterly cycle of our internal forecasts and then realizing the results before we start to provide external guidance for that business line because it's still new to us. But you get the gist of the scale of that business.
And the next question comes from Martin Pollock with FMR Holdings. S
Yes. Wonderful to see we're finally become an operational company with real business. Just 2 questions to start with. You've talked about the 2 entities, the Ultra gene ReWalk. When will we see some segment reporting that will truly get into the -- at least the operating line for both companies? At this point, should we expect that by fourth quarter? Or did you say beginning next year, we will see segment reporting? That will be the first question, please.
Good question. So I think right now we're making that determination with our auditors. There are certain accounting requirements around when segment reporting is justified. We plan to run the businesses as 1 business. This is not a case of 2 separate business entities that are just running in separate silos. There's going to be a lot of cross-pollination of our cost structure. And our entire commercial team is really supporting all of the product lines. So at this point, I don't know yet if we will, in fact, need to provide segment reporting because our intention is that we're not running these are separate segments. They are going to be one consolidated business line. But we still need to do more research into that. And certainly, we'll provide an update in terms of where the -- what the final determination is.
It seems that if that's the case, we'll never really get a chance to see what the trends on a transparent basis, what is the profitability of AlterG separate from ReWalk. I don't know that, that's -- there would be a reason not to separate them to different products. But I think that also ends up creating questions about where the cash -- where the earnings are coming from. It seems to me the 2 products are still discrete enough. So I really think it'd be very, very wise for you to provide more of that type of reporting, not just on the revenue line, but as it filters down to the EBIT line, you're suggesting already that you made some money even in that period that you reported that AlterG is profitable. What is the level of profitability there? I mean, what would you be expecting for that even if it came in a matter of discussion as opposed to the segment breakdown because I think we need to know that. Second question is when it comes to the cash burn -- it seems, for the first time, I've heard real aspirational comment that suggests that cash burn is coming down dramatically. You said significantly, but when you're saying we're expecting higher revenues, we're expecting a significant decline in cash use or cash burn. Are we still holding out to the notion that you'll never need additional financing and the cash on hand will be sufficient to go through 2024 and '25? But give us a little bit more perspective on that cash going into Q4 and then into next year. Certainly, I know you not really make a full year forecast, but what does significant decline mean? Can you amplify that because this is just -- it seems not enough to really get a good handle is it decline a burn rate of $2.5 million per quarter? Or is it -- is it $4 million? Or is it -- what number is that? I appreciate if you can give us some kind of clue into that.
Okay. I'll give some comments on this, Larry. First, on the things that are really going to reduce our investment to succeed with CMS has been very large, be it legal, be it other advisers, be it data collections, be it build-in infrastructure, we've succeeded. The investment paid off relative to getting to the endpoint that they were charged for, but we don't need and will not require the majority of those activities any longer as we go into next year. So you're going to see a significant reduction in efforts on government spend. We've talked a little bit about the VA. And we believe as this new act goes through, again, there will be a significant reduction on some of our activities there as well in terms of government policy. We also see a lot of operational efficiency. As we pointed out, our sales forces are going to be one sales force. It's no longer broken out. The same rep is going to the hospital selling multiple product lines. And that has its efficiency to it in a significant way with more territories, less travel. And to your point, do we believe we have sufficient cash to get to profitability? The answer is absolutely, we do. We see growth with CMS, with the VA, with new product lines with AlterG, we have 1 this year. We look to do another one in 2005 as well in the AlterG product line. They didn't have the cash to do those. That is some of the synergistic effect of this. We have to execute but we believe that we can. Relative to the amount of burn rate, that's a hard one, and we'd like to finish our -- all of our specific plans. But I'll scale it at least at some level. We're looking at reductions in burn rates in the direction of half year-over-year. The actual numbers will make visible as they occur, revenue is going up. Some of our expenses are going down. We know what we have to do, and we're going to do it.
So Larry, clearly, I think in previous quarters, you both have said you like that -- to some extent, a lot depends on the revenue growth at this point. And it seems that, that continues to be the case, but now you're also pointing out to certain expenses, real expenses that will not be there because of all the costs of integrating companies, putting them making the acquisition and what costs you no longer have to incur. So I don't want to put words in your mouth, but if you're saying by the time half of the burner, it could be mitigated or maybe run rate could be down 40%, 50%. I mean, should one assume that at some point, the run rate on cash burn in 2024, maybe quarter 1, quarter 2. And our run rate, we'll be down to that $2 million, $2.5 million. Is there any reason why your comments are pointing us to that direction?
We clearly expect our burn rate to go down quarter-over-quarter over quarter. We haven't quantified it. I'd like to quantify the exact dates I'm getting paid by CMS. So I could see the top line that's going to offset some of that bottom line. And that's going to become apparent to us. But that's why we're not being -- we can't give more specific guidance, but we expect to report reductions in burn rate every quarter in the year ahead.
Okay. Because it does seem that these comments are for the first time it to really point us to the lower expenses that will be incurred. That alone is very different than what you've said in the past where you've said, well, a lot will depend on revenue growth. You've implied there will be some costs that will be lower, but this seems to be -- these comments are really more significant as I'm hearing you.
One more question with regard to this legislation, the new build that's being proposed for the VA. I found it curious that for anybody that red disks for the first time I would have thought, "Oh, this is something brand new. Well, you've been selling to the VA from the very beginning and there was never a notion of this what accelerated ability to generate even more activity out of VA, what that is. And I would like to know whether -- when you talk about the VA itself, independent of CMS, assuming this bill goes through, and I don't know when that does happen. The number of cases that could literally end up being new sales at some point. Obviously, there is a sales cycle that takes place 6 months or so. But could the VA sales be exponentially much higher with the bill being approved?
Well, the bill being implemented and followed will change it. The best way to look at this is CMS for Medicare, Medicaid is 56% of the spinal core injury population in the United States. And if you just Medicare alone, it's 31%. The next largest single block in the United States is the veterans, which is roughly 9%. So this opens up the door for us if we get it properly into -- integrated into VA processes, access to our 2 biggest markets. The VA can only complement how wonderful they've been on the R&D side. It didn't translate as well as we would have hoped on the execution side. COVID got away, frankly, in a big way but we've seen that change in some behavior this year. As I indicated, we had 3 really active operating centers for the whole U.S. that we're really getting things done. We now have 9. That's -- by percentages, it sounds great, and I don't see what that matures is, but it certainly increases our revenue. And this bill that the Congress has taken through the house and going through the Senate shows the commitment, I think, of key people in Congress to taking care of veterans and we're -- we believe we'll build on that. We'll provide the process for it, but general Bergman, in particular, along with the others that cosponsored this bill. And they brought a U.S. Marine who is paralyzed and walking to the hill with them. They're quite serious about supporting this and supporting the veterans, and we think we'll build on that.
Just assuming that, let's say, the bill goes through the moment that happens, how does that change your strategy with regard to allocating some of those resources also straight in towards the VA potential patients. Has any change that takes place immediately recognizing this could open up a huge number of new cases?
It will open more cases, and I think it will do it gradually, but what we've done structurally and part of the whole design of both organic and inorganic growth through acquisition was to have a field presence that could implement well. The VA is really good in how they manage veterans, but they need support. They need good support for training. They need good support on a day-to-day basis in making sure these veterans get through the system, at least from a product supply end and the elements that we have to give them. With the larger sales organization, the design of that is to be able to call on more VAs as and help them and with any support that they require from industry and also do the same with CMS. We needed that large organization to implement on our sales goals. And that's why the combination of all these factors go together. The larger organization and team plus VA plus CMS are all favorable to allow growth, it will never be fast enough but it will grow.
Last question, if I may, Larry, certainly, when we announced the price per unit, $186,000 that you were essentially putting into the -- into your expectation or at least your request with CMS, stock to cost stock then retreated significantly when we saw the number, 94,000 or 600 or so you expressed that you were quite pleased. You also indicated that the possibility now is that will be a baseline to grow from, would the hope that you'll be getting some consideration for the stair-climbing approval as well as turning sharp corners. The number sounds like it's going to be higher than the '24 obviously, in implementation. Is there a number do you think no one could expect that the MS will provide additional funding for recognizing that Dave said exactly that. What is the number that you would say is one that would make you pleased? I would imagine that you are looking for $50,000 for that for you. But what kind of number is reasonable to expect?
Well, Marty, what I'm very pleased about is that CMS came forward and said, we want to use current market pricing as part of our consideration for a formula. And that's the right way to do it from a government policy point of view. So I actually dose big government policy, which I don't do very often. I don't want to put a specific number to it. We will go back and give them the invoices of the current model. They will put it in a formula or consider it, and we will work with that number. We being covered for 56% of the population and 31% specifically being the Medicare with the 25% being Medicaid matters. So we're going to be able to grow at whatever number they give us, but they came and asked for the right data. We're going to give them the right data and maybe slowly, but government policy is working. We're making progress in the 2 largest government entities that make up our business. And it's taken a lot of time and a lot of investment. But we're done with the investment and now it's time to move forward.
When you said market price or market data, you're clearly indicating it's higher than 94,000. You're implying some numbers that you would say that is more reasonable. Did you -- what is that number? I mean, is there a way for us to gauge what kind of market data you're thinking about? Or what is that kind of price? What are you -- what is the market?
The number is going to be CMS' number, not our number, and it will be for every person who's paralyzed. We believe it's going to be a number that works for our business. But I've got to let them do the process before I put a number out there. And that's not going to take too long. We get to present on November 29. Historically, they have given answers to those deliberations roughly late January, early February. And also, they have a lot of pending claims. They could choose to pay one before that or not. We're not far away from getting a good number...
That good number is a number that you would say is a step-up of the 94,600 right? That seems to be what you're suggesting, whatever that number is, okay? But that is the way I think the initial release suggested that they're willing to go back to the 2020 -- beyond the 2020, recognizing the new improvements. Clearly, the FDA approval for both Stair climbing being the case as well as turning quarters. So you would say that the 94,600 plus I think that's what seems to be what 1 you assume, right?
Well, clearly, we're presenting a 2023 number, which is they used a base number that they were very clear about. It was $125,000 that was published in the public documents. We have a list price of $186,000. They will consider that from our material we provide them, and they will put it in their formula, which is a fairly complex formula that is available on the CMS website, if you could pursue that. And it will -- should give us a number that we can work with. That is our -- that's all the data I can give you because it's all I have today.
Okay. Listen, I do want to -- it seems things are really moving in the right direction after all these years. We're finally getting closer to being the light at the end of the tunnel. I hope that clearly, this is a new day for ReWalk, all the best.
And this concludes the question-and-answer session. I would like to turn the floor to my calls for any closing comments.
First, I'd like to thank everybody for participating. And as I close the call, I talked about us moving into a new phase of execution. And that's what we're going to be able to start reporting on as we go into 2024. And it's time to pay attention to us in a different phase of our -- where our company is. And it's a phase of revenue growth and being prudent in managing our financial position to get this company to reduce its burn rate and to get to breakeven on the cash we have. I want to emphasize that's where we are pointing ourselves and that's where we're committed. So I look forward to future calls because I get to talk about these things, and I'll do the best we can with those. So with that, thank you, everyone, for your time today, and please reach shows if you have further questions.
Thank you. The conference has now concluded. Thank you for attending today's presentation, and you may now disconnect your lines.